Intercept to Present at Upcoming Investor Conferences

        Print
| Source: Intercept Pharmaceuticals, Inc.

NEW YORK, June 6, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced management will be participating in the following upcoming investor conferences:

  • Dr. Mark Pruzanski, Chief Executive Officer, will present at the Goldman Sachs 35th Annual Global Healthcare Conference at 10:40 a.m. PT on Thursday, June 12, 2014 in Los Angeles
  • Dr. Pruzanski will participate in the Citi NASH Workshop on Monday, June 23, 2014 in New York
  • Dr. Rachel McMinn, Chief Strategy Officer, will present at the JMP Securities Health Care Conference at 10:00 a.m. ET on Wednesday, June 25, 2014 in New York

Information for the availability of live webcasts for these events will be posted on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks following each event.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA has met the primary efficacy endpoint in five placebo-controlled clinical trials, including the recently completed POISE Phase 3 clinical trial in patients with PBC and two Phase 2 clinical trials in NASH and nonalcoholic fatty liver disease. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma (DSP). For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.

For more information about Intercept,
please contact Barbara Duncan or Senthil Sundaram,
both of Intercept Pharmaceuticals at 1-646-747-1000.
Media inquiries: 
Investor inquiries: